Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

This release contains forward-looking statements about Pfizer Oncology; our anticipated operating and financial performance, including financial guidance and projections; changes to Pfizer’s ...

Schmeltz has headed Pfizer's global oncology business for the last year. Pfizer The breast-cancer drug had its first major data presentation just three years before its US approval in 2015, Pfizer ...

Previously, Dr. Boshoff oversaw clinical research and product development activities for Pfizer’s Oncology portfolio, including 24 approved innovative cancer medicines and biosimilars in more ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer shifts oncology chief Schmeltz to new strategy role as rare disease head Varma fills in By Zoey Becker, Angus Liu Sep 2, 2022 11:18am Pfizer Andy Schmeltz rare diseases cancer drugs ...

Pfizer Oncology sets ambitious goal to develop 8 potential "blockbuster" cancer drugs by 2030, ... RCM leaders discuss strategy and lessons learned. Recommended Live Webinar on Jun 4, 2025 11:00 ...

Oncology will be a big part of that effort — Pfizer executives told investors earlier this year that they expect to have eight blockbuster cancer drugs by 2030, up from five now.

Apart from oncology, Pfizer’s portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others.

Nicholson joins Pfizer from Eli Lilly, where he spent more than 10 years as executive director of the U.S. oncology business unit and subsequently in an expanded role as global oncology platform ...

Pfizer Inc. today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology. Under his ...